Ranbaxy Laboratories Limited today entered into an in-licensing agreement with Ethypharm S.A., France for novel drug delivery system (NDDS) analgesic , Tramadol in the Indian market The agreement was signed with Ethypharm LL India (Ethypharm), the wholly-owned subsidiary of the French drug major for 50 mg strength, the company said in a statement.
The product will be supplied from Ethypharm's manufacturing facility near Mumbai and marketed and distributed by Ranbaxy under its brand name 'Trambax', it added.
Commenting on the agreement Ranbaxy India and Middle East Regional Director Sanjeev I Dani, said, the introduction of Trambax tablets will further strengthen thecompany's portfolio in the pain management segment.
'The Indian market of Tramadol is approximately Rs 15 crores annually and is expected to grow significantly with the addition of this Novel Drug Delivery System, making the administration of the product easier and more convenient to the patient,' Ethypharm LL India Chief Executive Officer Ajey Kumar said.
Curently, Ranbaxy has a basket of 30 novel products already on pharmacy shelves in the NDDS space in India. With the introduction of the NDDS product Trambax, Ranbaxy has so far launched 2 in-licenced products and has 5 more such products in the pipeline, for launch during the year, it added.
Tramadol is used for treatment of severe to moderate pain in trauma cases and is also used as an adjunct therapy in the treatment of cancer patients.